Gene editors steady despite latest leadership shake-up at FDA
Source: SeekingAlpha
2025-06-20 08:39:22 ET
More on Editas Medicine
- Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript)
- Editas Medicine: Do The Risks Outweigh The Rewards?
- RFK Jr. looks to fast track rare disease drug approvals (updated)
- Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit
- Seeking Alpha’s Quant Rating on Editas Medicine
Read the full article on Seeking Alpha
For further details see:
Gene editors steady despite latest leadership shake-up at FDA
Editas Medicine Inc.
NASDAQ: EDIT
EDIT Trading
2.45% G/L:
$2.67 Last:
1,085,358 Volume:
$2.61 Open:
EDIT Latest News
March 09, 2026 07:00:00 am
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates
EDIT Stock Data
$174,737,401
95,568,668
0.4%
71
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
